Mostly Cloudy 50°
Tag:

Ridgeback Bio

News
COVID-19: NJ Drug Manufacturer Merck Says New Antiviral Drug Shows Quick Reduction In Virus COVID-19: NJ Drug Manufacturer Merck Says New Antiviral Drug Shows Quick Reduction In Virus
Covid-19: NJ Drug Manufacturer Merck Says New Antiviral Drug Shows Quick Reduction In Virus Experimental antiviral drug molnupiravir being developed by New Jersey drug manufacturer Merck with Ridgeback Bio shows a quick reduction of the infectious virus in a study among participants with early COVID-19. Molnupiravir is being tested in a Phase 2/3 trial set to be completed in May. Merck will be provided with up to  $268.8 million in funding from the Biomedical Advanced Research and Development Authority within the U.S. Department of Health and Human Services. Associate Professor of Medicine at the University of North Carolina School of Medicine William Fis…

SHARE

by Cecilia Levine